701232-20-4

701232-20-4 structure

Name: DGAT-3
Chemical Name: 2-[4-[4-(4-amino-7,7-dimethylpyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]acetic acid
CAS Number: 701232-20-4
Molecular Formula: C₂₂H₂₆N₄O₃
Molecular Weight: 394.467
Catalog: Signaling Pathways Metabolic Enzyme/Protease Acyltransferase
Create Date: 2018-12-29 16:26:30
Modify Date: 2026-07-16 10:07:48
T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.IC50 value:Target: DGAT1T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.

Name	2-[4-[4-(4-amino-7,7-dimethylpyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexyl]acetic acid
Synonyms	trans-4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]cyclohexaneacetic acid 2-((1,4-trans)-4-(4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)- phenyl)cyclohexyl)acetic acid T863 (DGAT-3) T863 T863, 10 mM in DMSO T-863 trans-Cyclohexaneacetic-acid,-4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl] Mino-7,7-diMethyl-2-((1r,4r)-4-(4-(4-a7H-pyriMido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid DGAT-1 inhibitor T863 (DGAT-3) ，S0359 trans-2-(4-(4-(4-amino-7,7-diMethyl-7H-pyriMido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid cc-141 Cyclohexaneacetic acid, 4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]-, trans trans-4-(4-(4-amino-7,7-dimethyl-7h-pyrimido(4,5-b)(1,4)oxazin-6-yl)phenyl)cyclohexaneacetic acid Diglyceride acyltransferase,inhibit,acyl-CoA:cholesterol acyltransferase,T 863,,Inhibitor,Acyltransferase,mono- acylglycerol acyltransferase,Diacylglycerol acyltransferase

Description	T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.IC50 value:Target: DGAT1T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Acyltransferase Research Areas >> Metabolic Disease
References	[1]. Cao J, et al. Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem. 2011 Dec 2;286(48):41838-51. [2]. Dow RL, et al. Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. Bioorg Med Chem Lett. 2011 Oct 15;21(20):6122-5. [3]. Qian Y, et al. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. J Med Chem. 2011 Apr 14;54(

RIDADR	NONH for all modes of transport